Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05257993 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 1 to Phase 1/2v5 Show 5 more changesShow less
    • Enrollment target: 30 to 71
    • Primary completion date: Mar 2026 to Apr 2030
    • Primary endpoints: 1 to 2
    • Study completion date: Jun 2026 to Apr 2030
    • Eligibility criteria expanded, about 53 words
  2. Study sites: 1 to 4
    • Study completion date: Sep 2026 to Jun 2026
    v4
  3. Primary completion date: Dec 2024 to Mar 2026
    • Enrollment target: 24 to 30
    • Study completion date: Dec 2024 to Sep 2026
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Aug 2023 to Dec 2024
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2022 to Mar 30, 2022
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer
Trial Details
NCT Number NCT05257993
Lead Sponsor Onconic Therapeutics Inc.
Conditions
(from sponsor)		 Pancreatic Ductal Adenocarcinoma
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov